Skip to content

Price / sales at other companies

Incyte logo
IncyteINCY
3.5×+0.8×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
176.3×+173×
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
460.2×+450×
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
132.1×+102×
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
28.6×+28.2×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
6.9×+1.8×

Other financials

Income statement

See full
Revenue$2.0M+37.2%
Gross profit$1.6M+68.7%
Operating income-$22.2M-22.7%
Net income-$19.8M-31.4%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$28.7M-5.6%
Total debt$2.0M-20.1%
Total equity$143.6M-0.3%
Total assets$198.7M+0.3%

Cash flow

See full
Operating cash flow-$18.1M-39.0%
CapEx$13.0K-69.8%
Free cash flow-$18.2M-38.6%

Valuation

See full
Market cap$685.75M+337%
Enterprise value$659.07M+410%

Profitability

See full
Gross margin76.3%-9.7pp
Operating margin-961.9%+259pp
Net margin-832.6%+132pp
FCF margin-624.9%

Returns & leverage

See full
Return on equity-48.4%-15.4pp
Debt / equity0.0×
Current ratio-1.0×

Where this comes from

Calculated from Aclaris Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aclaris Therapeutics's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aclaris Therapeutics's price / sales?
Aclaris Therapeutics (ACRS) reported price / sales of 54.3× in Q1 2026.
How has Aclaris Therapeutics's price / sales changed year-over-year?
Aclaris Therapeutics's price / sales increased by 483.1% year-over-year, from 9.3× to 54.3×.
What is the long-term trend for Aclaris Therapeutics's price / sales?
Over 5 years (2020 to 2025), Aclaris Therapeutics's price / sales has grown at a -7.4% compound annual growth rate (CAGR), from 61.1× to 41.7×.
What does price / sales mean?
Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.